New research article in The Lancet Infectious Diseases>

#Rosuvastatin adjunctive therapy for #rifampicin-susceptible pulmonary #tuberculosis: a phase 2b, randomised, open-label, multicentre trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2823%2900067-1/fulltext

#TB